ConcertAI has recently acquired CancerLinq, a real-world data platform initiated by the American Society of Clinical Oncology (ASCO) a decade ago, dedicated to advancing oncology research. Headquartered in Cambridge, Massachusetts, ConcertAI specializes in real-world evidence and generative artificial intelligence solutions. The acquisition involves a $250 million investment to bolster CancerLinq’s capabilities in utilizing real-world data, machine learning, analytics, and other advanced technologies. This infusion of resources aims to empower users in enhancing cancer care and research.
CancerLinq, having accumulated clinical data from nearly 7 million patient records across more than 100 cancer centers and oncology practices, focuses on compiling, harmonizing, and analyzing de-identified clinical data, including treatment details, molecular profiles, and outcomes. Under ConcertAI’s ownership, CancerLinq will persist in its mission to improve the quality of cancer care, advance precision medicine principles, expand real-world datasets for research, and support a new clinical trials initiative evolving from TriaLinq concepts.
The collaboration with ASCO remains intact, as evidenced by a multiyear cooperation agreement. ConcertAI, in partnership with ASCO, plans to enhance clinical trial data, make trials more accessible and participant-friendly, develop clinical decision support, and facilitate automated electronic medical record (EMR) integration. ASCO CEO Clifford Hudis expressed confidence that this agreement will amplify CancerLinq’s impact, furthering its support for quality improvement initiatives and facilitating research through the CancerLinq Discovery data. Additionally, CancerLinq is anticipated to play a role in supporting cancer centers seeking recognition as patient-centered, value-based care providers under ASCO’s recently launched ASCO Certified program.